News summary
[Minovantis: Its holding subsidiary Prophenolate Fumarate Tenofovir API Passed CDE Technical Review] Securities Times e Company Newsrouletteseries, Minotis (603538) announced on the evening of May 27rouletteseriesRecently, the company's holding subsidiary Zhejiang Minovanoshi Propifenolate Fumarate and Tenofovir API passed the National Drug Administrationrouletteseries.rouletteseries..
Newsletter text
[Minohua: Holding subsidiary Propifenol Tenofovir Fumarate Bulk Drug Substance Passed CDE Technical Review] Securities Times e Company News, Minovantis (603538) announced on the evening of May 27 that recently, the company's holding subsidiary Zhejiang Minovantis Propifenol Tenofovir Bulk Drug Substance Passed the technical review of the State Food and Drug Administration Center for Drug Evaluation (referred to as "CDE"), and the registration number changed to "A" status on the CDE Registration Information Announcement Platform for Drug APIs, pharmaceutical excipients and pharmaceutical packaging materials. The drug is indicated for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older, weighing at least 35kg).
